

**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*

**ANDA 76-553**

**APPROVAL LETTER**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

ANDA 76-553

Food and Drug Administration  
Rockville MD 20857

JUL 28 2004

SICOR Pharmaceuticals, Inc.  
Attention: Elvia O. Gustavson  
19 Hughes  
Irvine, CA 92618-1902

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated November 27, 2002, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Medroxyprogesterone Acetate Injectable Suspension USP, (Contraceptive Injection), 150 mg/mL, packaged in 150 mg/1 mL single-dose vials.

Reference is also made to your amendments dated April 25, and December 12, 2003, and February 20, April 15, May 17, May 20, May 26, June 22, and July 27, 2004.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Depo-Povera<sup>®</sup> Injectable Suspension, 150 mg/mL, of Pharmacia and Upjohn Company). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration  
Division of Drug Marketing, Advertising, and Communications, HFD-42  
5600 Fishers Lane  
Rockville, MD 20857

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications (HFD-42) with a completed Form FDA 2253 at the time of their initial use.

Sincerely,  
  
(b)(6)

Gary Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research